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A meta-analysis by Wang et al. [1] assessing hypertension
risk with ramucirumab use in patients with cancer was
recently published in Clinical Drug Investigation. The
authors concluded that ramucirumab treatment was asso-
ciated with a significant increase in hypertension risk in
cancer patients, and warned that treatment efficacy may be
reduced due to the need to manage hypertension.
We acknowledge hypertension as an adverse reaction
for ramucirumab. This is highlighted in the compound’s
package insert. However, the presentation by Wang et al.
of the clinical severity of these events is misleading.
An analysis of pooled data was performed across six
Phase III trials (ramucirumab N = 2748, placebo
N = 2248). In this analysis, 21.3 % (n = 585) of patients
taking ramucirumab experienced hypertension of any grade
during treatment, versus 7.4 % (n = 167) for patients
taking placebo. This translates to an increase of 13.9 % in
the number of patients developing any grade hypertension,
or about 1 in 7. More severe hypertension (CGrade 3) was
seen in 9 % (n = 246) of patients taking ramucirumab, and
2.5 % (n = 57) of patients taking placebo, a 6.5 % in-
crease, or approximately 1 in 15 patients. These percent-
ages coincide relatively well with the data stated in the
Wang et al. meta-analysis. However, of those patients ex-
periencing hypertension, only eight cases (\2 %) led to
discontinuation of any study treatment, showing that the
hypertension was manageable.
These additional data suggest that although hypertension
is a recognized adverse event in ramucirumab clinical tri-
als, it was manageable and resulted in low rates of dis-
continuation across six multinational clinical phase 3 trials.
Therefore, the suggestion by Wang et al. that hypertension
can have an effect on treatment efficacy is unsupported by
data.
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